<?xml version="1.0" encoding="UTF-8"?>
<ref id="B70" class="ref">
 <mixed-citation publication-type="journal" class="mixed-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Usta</surname>
    <given-names class="given-names">J.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Kreydiyyeh</surname>
    <given-names class="given-names">S.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Knio</surname>
    <given-names class="given-names">K.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Barnabe</surname>
    <given-names class="given-names">P.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Bou-Moughlabay</surname>
    <given-names class="given-names">Y.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Dagher</surname>
    <given-names class="given-names">S.</given-names>
   </name>
  </person-group> (
  <year class="year">2009</year>). 
  <article-title class="article-title">Linalool decreases HepG2 viability by inhibiting mitochondrial complexes I and II, increasing reactive oxygen species and decreasing ATP and GSH levels</article-title>. 
  <source class="source">Chem. Biol. Interact.</source>
  <volume class="volume">180</volume>, 
  <fpage class="fpage">39</fpage>â€“
  <lpage class="lpage">46</lpage>. 
  <pub-id pub-id-type="doi" class="pub-id">10.1016/j.cbi.2009.02.012</pub-id>
  <?supplied-pmid 19428344?>
  <pub-id pub-id-type="pmid" class="pub-id">19428344</pub-id>
 </mixed-citation>
</ref>
